Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1890 2
1953 1
1954 1
1982 1
2001 1
2003 2
2004 5
2005 7
2006 8
2007 10
2008 14
2009 15
2010 10
2011 9
2012 11
2013 8
2014 5
2015 5
2016 3
2017 7
2018 9
2019 12
2020 15
2021 16
2022 27
2023 21
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

185 results

Results by year

Filters applied: . Clear all
Page 1
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B; ORAL Standard Investigators. van Vollenhoven RF, et al. N Engl J Med. 2012 Aug 9;367(6):508-19. doi: 10.1056/NEJMoa1112072. N Engl J Med. 2012. PMID: 22873531 Free article. Clinical Trial.
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS; ORAL Strategy investigators. Fleischmann R, et al. Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5. Epub 2017 Jun 16. Lancet. 2017. PMID: 28629665 Clinical Trial.
Are Conspiracy Theories Harmless?
Douglas KM. Douglas KM. Span J Psychol. 2021 Feb 22;24:e13. doi: 10.1017/SJP.2021.10. Span J Psychol. 2021. PMID: 33612140
Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
Suhler EB, Jaffe GJ, Fortin E, Lim LL, Merrill PT, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Van Calster J, Cimino L, Adan A, Goto H, Kaburaki T, Kramer M, Vitale AT, Kron M, Song AP, Liu J, Pathai S, Douglas KM, Schlaen A, Muccioli C, Van Velthoven MEJ, Zierhut M, Rosenbaum JT. Suhler EB, et al. Among authors: douglas km. Ophthalmology. 2021 Jun;128(6):899-909. doi: 10.1016/j.ophtha.2020.10.036. Epub 2020 Nov 3. Ophthalmology. 2021. PMID: 33157077 Free article. Clinical Trial.
Cognitive enhancement therapy for mood disorders: A new paradigm?
Douglas KM, Peckham A, Porter R, Hammar A. Douglas KM, et al. Aust N Z J Psychiatry. 2019 Dec;53(12):1148-1150. doi: 10.1177/0004867419873711. Epub 2019 Sep 13. Aust N Z J Psychiatry. 2019. PMID: 31516027 Free PMC article. No abstract available.
185 results